Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.

× No keyword cloud information.

5 in total

Review 1. Rosiglitazone : a review of its use in type 2 diabetes mellitus.

Authors: Emma D Deeks; Susan J Keam
Journal: Drugs Date: 2007 Impact factor: 9.546

2. Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.

Authors: Graziella E Ronsein; Gissette Reyes-Soffer; Yi He; Michael Oda; Henry Ginsberg; Jay W Heinecke
Journal: Mol Cell Proteomics Date: 2015-12-14 Impact factor: 5.911

3. Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.

Authors: Michel Farnier; Qian Dong; Arvind Shah; Amy O Johnson-Levonas; Philippe Brudi
Journal: Lipids Health Dis Date: 2011-11-16 Impact factor: 3.876

4. The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients.

Authors: Jussi Sutinen
Journal: PPAR Res Date: 2008-12-01 Impact factor: 4.964

5. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.

Authors: Peter E Linz; Laura C Lovato; Robert P Byington; Patrick J O'Connor; Lawrence A Leiter; Daniel Weiss; Rex W Force; John R Crouse; Faramarz Ismail-Beigi; Debra L Simmons; Vasilios Papademetriou; Henry N Ginsberg; Marshall B Elam
Journal: Diabetes Care Date: 2013-12-02 Impact factor: 19.112

5 in total